

Zhi-Ming Shao

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1811769/zhi-ming-shao-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

230 papers	8,514 citations	39 h-index	86 g-index
239 ext. papers	11,162 ext. citations	7.9 avg, IF	6.02 L-index

#	Paper	IF	Citations
230	Comprehensive metabolomics expands precision medicine for triple-negative breast cancer.. <i>Cell Research</i> , 2022 ,	24.7	7
229	Copy number amplification of ENSA promotes the progression of triple-negative breast cancer via cholesterol biosynthesis.. <i>Nature Communications</i> , 2022 , 13, 791	17.4	2
228	Pharmacological disruption of the MTDH-SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer.. <i>Nature Cancer</i> , 2022 , 3, 60-74	15.4	4
227	Small-molecule inhibitors that disrupt the MTDH-SND1 complex suppress breast cancer progression and metastasis.. <i>Nature Cancer</i> , 2022 , 3, 43-59	15.4	4
226	O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF- β signaling to breast cancer progression.. <i>Cell Death and Differentiation</i> , 2022 ,	12.7	4
225	AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359221083956	5.4	4
224	Abstract P2-13-11: Response to anti-HER2 neoadjuvant chemotherapy in invasive breast cancers with different HER2 FISH-positive patterns. <i>Cancer Research</i> , 2022 , 82, P2-13-11-P2-13-11	10.1	
223	Tumor-derived Jagged1 promotes cancer progression through immune evasion.. <i>Cell Reports</i> , 2022 , 38, 110492	10.6	1
222	Proteome-centric cross-omics characterization and integrated network analyses of triple-negative breast cancer.. <i>Cell Reports</i> , 2022 , 38, 110460	10.6	0
221	Integrated analysis reveals the molecular features of fibrosis in triple-negative breast cancer.. <i>Molecular Therapy - Oncolytics</i> , 2022 , 24, 624-635	6.4	0
220	The early-stage triple-negative breast cancer landscape derives a novel prognostic signature and therapeutic target.. <i>Breast Cancer Research and Treatment</i> , 2022 , 1	4.4	0
219	Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial.. <i>Molecular Cancer</i> , 2022 , 21, 84	42.1	4
218	The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer.. <i>Cell Metabolism</i> , 2022 ,	24.6	8
217	Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 884-892	9.7	6
216	Large-scale genomic sequencing reveals adaptive opportunity of targeting mutated-PI3K in early and advanced HER2-positive breast cancer. <i>Clinical and Translational Medicine</i> , 2021 , 11, e589	5.7	0
215	Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer 2021 , 9,		1
214	Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor. <i>Oncogene</i> , 2021 , 40, 2323-2334	9.2	1

213	Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Early Triple-Negative Breast Cancer-Reply. <i>JAMA Oncology</i> , 2021 , 7, 461	13.4	
212	Microcalcification-Based Tumor Malignancy Evaluation in Fresh Breast Biopsies with Hyperspectral Stimulated Raman Scattering. <i>Analytical Chemistry</i> , 2021 , 93, 6223-6231	7.8	6
211	Cyclophosphamide-Free Adjuvant Chemotherapy for Ovarian Protection in Young Women With Breast Cancer: A Randomized Phase 3 Trial. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1352-1359	8.7	3
210	Serum HER2 levels predict treatment efficacy and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant treatment. <i>Gland Surgery</i> , 2021 , 10, 1300-1314	2.2	1
209	Tumor Size Still Impacts Prognosis in Breast Cancer With Extensive Nodal Involvement. <i>Frontiers in Oncology</i> , 2021 , 11, 585613	5.3	4
208	De-escalation of five years adjuvant endocrine therapy duration in patients with ER-low positive (immunohistochemical 1% to 10%) early-stage breast cancer: A propensity-matched analysis from the prospectively maintained database.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 538-538	2.2	
207	Genomic features of rapid versus late relapse in triple negative breast cancer. <i>BMC Cancer</i> , 2021 , 21, 568	4.8	2
206	LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021 , 20, 452-459	2.1	0
205	Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 98	22.4	24
204	Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial. <i>The Lancet Regional Health - Western Pacific</i> , 2021 , 11, 100158	5	2
203	Bulk and single-cell transcriptome profiling reveal the metabolic heterogeneity in human breast cancers. <i>Molecular Therapy</i> , 2021 , 29, 2350-2365	11.7	4
202	Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 2935-2944	4.9	1
201	GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer 2021 , 9,		2
200	Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. <i>Cell Research</i> , 2021 , 31, 178-186	24.7	43
199	Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations. <i>Breast Cancer Research and Treatment</i> , 2021 , 185, 371-380	4.4	1
198	Breast Cancer-Specific Mortality in Small-Sized Tumor with Stage IV Breast Cancer: A Population-Based Study. <i>Oncologist</i> , 2021 , 26, e241-e250	5.7	1
197	Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. <i>Cell Metabolism</i> , 2021 , 33, 51-64.e9	24.6	57
196	Novel aptasensor-based assay of sonic hedgehog ligand for detection of portal vein invasion of hepatocellular carcinoma. <i>Biosensors and Bioelectronics</i> , 2021 , 174, 112738	11.8	4

195	Triple-negative breast cancer: new treatment strategies in the era of precision medicine. <i>Science China Life Sciences</i> , 2021 , 64, 372-388	8.5	5
194	The advance of adjuvant treatment for triple-negative breast cancer. <i>Cancer Biology and Medicine</i> , 2021 ,	5.2	1
193	A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes. <i>Annals of Translational Medicine</i> , 2021 , 9, 301	3.2	1
192	Estrogen receptor-low breast cancer: Biology chaos and treatment paradox. <i>Cancer Communications</i> , 2021 , 41, 968-980	9.4	4
191	PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021 , 81, 5491-5505	10.1	5
190	Spatiotemporal Patterns of Loco-Regional Recurrence After Breast-Conserving Surgery. <i>Frontiers in Oncology</i> , 2021 , 11, 690658	5.3	0
189	Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 312	21	8
188	Trend and survival benefit of contralateral prophylactic mastectomy among men with stage I-III unilateral breast cancer in the USA, 1998-2016. <i>Breast Cancer Research and Treatment</i> , 2021 , 190, 503-515	4.4	0
187	Prognostic Effect of Microenvironment Phenotype in Triple-Negative Breast Cancer: Biomarker Analysis of a Prospective Trial. <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 752154	5.6	1
186	Delayed initiation of radiation therapy is associated with inferior outcomes for breast cancer patients with hormone receptor-negative tumors after breast-conserving surgery. <i>Gland Surgery</i> , 2021 , 10, 2631-2643	2.2	0
185	ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression. <i>Cancer Research</i> , 2021 , 81, 5919-5934	10.1	9
184	Homologous recombination deficiency and glycolysis-related pathway in adjuvant chemotherapy for triple-negative breast cancer: A genomic landscape and biomarker assessment of the PATTERN trial. <i>Clinical and Translational Medicine</i> , 2021 , 11, e513	5.7	
183	A Novel Seven Gene Signature-Based Prognostic Model to Predict Distant Metastasis of Lymph Node-Negative Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 746763	5.3	1
182	Pregnancy-specific glycoprotein 9 acts as both a transcriptional target and a regulator of the canonical TGF- β /Smad signaling to drive breast cancer progression. <i>Clinical and Translational Medicine</i> , 2020 , 10, e245	5.7	3
181	Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer. <i>Annals of Translational Medicine</i> , 2020 , 8, 342	3.2	0
180	Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity. <i>Nature Cell Biology</i> , 2020 , 22, 716-727	23.4	28
179	Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance. <i>Nature Cell Biology</i> , 2020 , 22, 701-715	23.4	31
178	Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies. <i>Cancer</i> , 2020 , 126, 3209-3218	6.4	8

177	LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer. <i>Molecular Cancer</i> , 2020 , 19, 87	42.1	22
176	Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. <i>Oncologist</i> , 2020 , 25, e1481-e1491	5.7	27
175	The Burden and Trends of Breast Cancer From 1990 to 2017 at the Global, Regional, and National Levels: Results From the Global Burden of Disease Study 2017. <i>Frontiers in Oncology</i> , 2020 , 10, 650	5.3	25
174	Concordance of Hormone Receptor Status and BRCA1/2 Mutation Among Women With Synchronous Bilateral Breast Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 27	5.3	2
173	Neoadjuvant systemic therapy does not compromise local control after breast-conserving surgery: a single-center, propensity score matching study in China.. <i>Translational Cancer Research</i> , 2020 , 9, 155-165	8.3	1
172	Association between socioeconomic factors at diagnosis and survival in breast cancer: A population-based study. <i>Cancer Medicine</i> , 2020 , 9, 1922-1936	4.8	16
171	Value of CXCL8-CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study. <i>Breast Cancer Research and Treatment</i> , 2020 , 181, 561-570	4.4	5
170	KCNN4 induces multiple chemoresistance in breast cancer by regulating BCL2A1. <i>American Journal of Cancer Research</i> , 2020 , 10, 3302-3315	4.4	2
169	Multiple cancer susceptible genes sequencing in BRCA-negative breast cancer with high hereditary risk. <i>Annals of Translational Medicine</i> , 2020 , 8, 1417	3.2	1
168	Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells. <i>Autophagy</i> , 2020 , 16, 1061-1076	10.2	17
167	Breast Cancer: IL1R2 Blockade Suppresses Breast Tumorigenesis and Progression by Impairing USP15-Dependent BMI1 Stability (Adv. Sci. 1/2020). <i>Advanced Science</i> , 2020 , 7, 2070002	13.6	78
166	Subtype-Guided F-FDG PET/CT in Tailoring Axillary Surgery Among Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: A Feasibility Study. <i>Oncologist</i> , 2020 , 25, e626-e633	5.7	6
165	Modified lymph node ratio improves the prognostic predictive ability for breast cancer patients compared with other lymph node staging systems. <i>Breast</i> , 2020 , 49, 93-100	3.6	4
164	Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer. <i>Theranostics</i> , 2020 , 10, 11092-11109	12.1	9
163	Immunotherapy for advanced hepatocellular carcinoma, where are we?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020 , 1874, 188441	11.2	22
162	Value of stereotactic 11-gauge vacuum-assisted breast biopsy in non-palpable suspicious calcifications: an eight-year single institution experience with 587 patients. <i>Gland Surgery</i> , 2020 , 9, 1258-1266	2.2	1
161	Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing. <i>Nature Communications</i> , 2020 , 11, 5679	17.4	8
160	Natural killer cells in cancer biology and therapy. <i>Molecular Cancer</i> , 2020 , 19, 120	42.1	101

159	Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 1390-1396	13.4	50
158	Maintenance chemotherapy is effective in patients with metastatic triple negative breast cancer after first-line platinum-based chemotherapy. <i>Annals of Palliative Medicine</i> , 2020 , 9, 3018-3027	1.7	1
157	Deubiquitinase USP20 promotes breast cancer metastasis by stabilizing SNAI2. <i>Genes and Development</i> , 2020 , 34, 1310-1315	12.6	9
156	Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers. <i>Theranostics</i> , 2020 , 10, 10531-10547	12.1	9
155	SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer. <i>Theranostics</i> , 2020 , 10, 10940-10956	12.1	13
154	Molecular subtypes and precision treatment of triple-negative breast cancer. <i>Annals of Translational Medicine</i> , 2020 , 8, 499	3.2	38
153	Ultrasonographic appearance of triple-negative invasive breast carcinoma is associated with novel molecular subtypes based on transcriptomic analysis. <i>Annals of Translational Medicine</i> , 2020 , 8, 435	3.2	4
152	Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers. <i>Cell Research</i> , 2019 , 29, 832-845	24.7	19
151	Downregulation of transgelin 2 promotes breast cancer metastasis by activating the reactive oxygen species/nuclear factor- κ B signaling pathway. <i>Molecular Medicine Reports</i> , 2019 , 20, 4045-4258	2.9	6
150	Invasive micropapillary carcinoma of the breast had no difference in prognosis compared with invasive ductal carcinoma: a propensity-matched analysis. <i>Scientific Reports</i> , 2019 , 9, 286	4.9	16
149	Is core needle biopsy effective at diagnosing male breast lesions?. <i>Breast Cancer Research and Treatment</i> , 2019 , 177, 507-511	4.4	2
148	Unveiling novel targets of paclitaxel resistance by single molecule long-read RNA sequencing in breast cancer. <i>Scientific Reports</i> , 2019 , 9, 6032	4.9	8
147	Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial. <i>Cancer</i> , 2019 , 125, 2185-2193	6.4	10
146	Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 5002-5014	12.9	120
145	Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity. <i>Clinical Cancer Research</i> , 2019 , 25, 3658-3672	12.9	21
144	Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. <i>Cancer Cell</i> , 2019 , 35, 428-440.e5	24.3	239
143	The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation. <i>Science Advances</i> , 2019 , 5, eaat9820	14.3	49
142	High expression of Linc00959 predicts poor prognosis in breast cancer. <i>Cancer Cell International</i> , 2019 , 19, 39	6.4	1

141	Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer. <i>International Journal of Cancer</i> , 2019 , 145, 2850-2860	7.5	7
140	Toll-like receptor 3 acts as a suppressor gene in breast cancer initiation and progression: a two-stage association study and functional investigation. <i>Oncolmmunology</i> , 2019 , 8, e1593801	7.2	9
139	Transcriptome analysis of luminal breast cancer reveals a role for LOL in tumor progression and tamoxifen resistance. <i>International Journal of Cancer</i> , 2019 , 145, 842-856	7.5	12
138	Integrative 3QUntranslated Region-Based Model to Identify Patients with Low Risk of Axillary Lymph Node Metastasis in Operable Triple-Negative Breast Cancer. <i>Oncologist</i> , 2019 , 24, 22-30	5.7	10
137	Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant. <i>Cancer Medicine</i> , 2019 , 8, 6212-6220	4.8	6
136	Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer. <i>Theranostics</i> , 2019 , 9, 4935-4945	12.1	15
135	High expression of metabolic enzyme PFKFB4 is associated with poor prognosis of operable breast cancer. <i>Cancer Cell International</i> , 2019 , 19, 165	6.4	16
134	A Nomogram Predicting Lymph Node Metastasis in T1 Breast Cancer based on the Surveillance, Epidemiology, and End Results Program. <i>Journal of Cancer</i> , 2019 , 10, 2443-2449	4.5	11
133	USP9X stabilizes BRCA1 and confers resistance to DNA-damaging agents in human cancer cells. <i>Cancer Medicine</i> , 2019 , 8, 6730-6740	4.8	14
132	CapG promotes resistance to paclitaxel in breast cancer through transactivation of PIK3R1/P50. <i>Theranostics</i> , 2019 , 9, 6840-6855	12.1	19
131	Prognostic value of primary tumor surgery in stage IV breast cancer patients with different metastatic burdens: a propensity score-matched and population-based study.. <i>Translational Cancer Research</i> , 2019 , 8, 614-625	0.3	
130	Deubiquitinase ubiquitin-specific protease 9X regulates the stability and function of E3 ubiquitin ligase ring finger protein 115 in breast cancer cells. <i>Cancer Science</i> , 2019 , 110, 1268-1278	6.9	8
129	Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival. <i>Oncologist</i> , 2019 , 24, 753-761	5.7	13
128	eEF2 kinase mediated autophagy as a potential therapeutic target for paclitaxel-resistant triple-negative breast cancer. <i>Annals of Translational Medicine</i> , 2019 , 7, 783	3.2	15
127	Toll-like receptor 3 -926T>A increased the risk of breast cancer through decreased transcriptional activity. <i>Oncolmmunology</i> , 2019 , 8, e1673126	7.2	4
126	LINC02273 drives breast cancer metastasis by epigenetically increasing AGR2 transcription. <i>Molecular Cancer</i> , 2019 , 18, 187	42.1	69
125	Dimerization of MORC2 through its C-terminal coiled-coil domain enhances chromatin dynamics and promotes DNA repair. <i>Cell Communication and Signaling</i> , 2019 , 17, 160	7.5	10
124	Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling. <i>Cancer Cell</i> , 2019 , 35, 64-80.e7	24.3	74

123	Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer. <i>Breast</i> , 2019 , 43, 97-104	3.6	14
122	Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics. <i>Breast Cancer Research and Treatment</i> , 2019 , 173, 225-237	4.4	27
121	Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial. <i>Cancer Management and Research</i> , 2019 , 11, 299-307	3.6	4
120	Prognostic factors in breast phyllodes tumors: a nomogram based on a retrospective cohort study of 404 patients. <i>Cancer Medicine</i> , 2018 , 7, 1030-1042	4.8	14
119	PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression. <i>Cancer Research</i> , 2018 , 78, 3190-3206	10.1	35
118	Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. <i>Nature Communications</i> , 2018 , 9, 1357	17.4	63
117	Clinicopathologic features and prognoses of different histologic types of triple-negative breast cancer: A large population-based analysis. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 420-428	3.6	30
116	IL6 blockade potentiates the anti-tumor effects of ß-secretase inhibitors in Notch3-expressing breast cancer. <i>Cell Death and Differentiation</i> , 2018 , 25, 330-339	12.7	30
115	CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. <i>PLoS Biology</i> , 2018 , 16, e2005869	9.7	39
114	Decreased survival in patients with carcinoma of axillary tail versus upper outer quadrant breast cancers: a SEER population-based study. <i>Cancer Management and Research</i> , 2018 , 10, 1133-1141	3.6	4
113	Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis. <i>Cancer Medicine</i> , 2018 , 7, 4156-4169	4.8	16
112	Interaction between glutathione S-transferase M1-null/present polymorphism and adjuvant chemotherapy influences the survival of breast cancer. <i>Cancer Medicine</i> , 2018 , 7, 4202-4207	4.8	9
111	MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer. <i>BMC Cancer</i> , 2018 , 18, 74	4.8	35
110	Epidemiology and survival outcomes of mucinous adenocarcinomas: A SEER population-based study. <i>Scientific Reports</i> , 2018 , 8, 6117	4.9	11
109	Cancer-Associated MORC2-Mutant M276I Regulates an hnRNPM-Mediated CD44 Splicing Switch to Promote Invasion and Metastasis in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2018 , 78, 5780-5792	10.1	40
108	The Prognostic Value of Nodal Staging in Triple-Negative Breast Cancer - A Cohort from China. <i>Scientific Reports</i> , 2018 , 8, 9007	4.9	9
107	Protein C receptor stimulates multiple signaling pathways in breast cancer cells. <i>Journal of Biological Chemistry</i> , 2018 , 293, 1413-1424	5.4	14
106	Nomogram for predicting preoperative lymph node involvement in patients with invasive micropapillary carcinoma of breast: a SEER population-based study. <i>BMC Cancer</i> , 2018 , 18, 1085	4.8	7

105	DSCAM-AS1 regulates the G/S cell cycle transition and is an independent prognostic factor of poor survival in luminal breast cancer patients treated with endocrine therapy. <i>Cancer Medicine</i> , 2018 , 7, 6137-6146	4.8	23
104	Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer. <i>Theranostics</i> , 2018 , 8, 6386-6399	12.1	18
103	miR-200c/141 Regulates Breast Cancer Stem Cell Heterogeneity via Targeting HIPK1/β-Catenin Axis. <i>Theranostics</i> , 2018 , 8, 5801-5813	12.1	42
102	Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients. <i>BMC Cancer</i> , 2018 , 18, 909	4.8	16
101	Effect of functional genetic variants in chemokine decoy receptors on the recurrence risk of breast cancer. <i>Cancer Medicine</i> , 2018 , 7, 5497-5504	4.8	5
100	Development and Validation of Nomograms for Predicting Overall and Breast Cancer-Specific Survival in Young Women with Breast Cancer: A Population-Based Study. <i>Translational Oncology</i> , 2018 , 11, 1334-1342	4.9	10
99	MicroRNA-493 is a prognostic factor in triple-negative breast cancer. <i>Cancer Science</i> , 2018 , 109, 2294-2301	10.9	18
98	Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 162, 39-48	4.4	21
97	Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer. <i>Scientific Reports</i> , 2017 , 7, 1134	4.9	4
96	Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. <i>Scientific Reports</i> , 2017 , 7, 45411	4.9	91
95	Phosphorylated eIF2 α predicts disease-free survival in triple-negative breast cancer patients. <i>Scientific Reports</i> , 2017 , 7, 44674	4.9	21
94	The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing. <i>International Journal of Cancer</i> , 2017 , 141, 129-142	7.5	61
93	PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. <i>International Journal of Cancer</i> , 2017 , 140, 1384-1395	7.5	26
92	RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 514-522	12.9	84
91	Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer. <i>OncoTargets and Therapy</i> , 2017 , 10, 5739-5744	4.4	14
90	The different outcomes between breast-conserving surgery and mastectomy in triple-negative breast cancer: a population-based study from the SEER 18 database. <i>Oncotarget</i> , 2017 , 8, 4773-4780	3.3	23
89	Mixed invasive ductal and lobular carcinoma has distinct clinical features and predicts worse prognosis when stratified by estrogen receptor status. <i>Scientific Reports</i> , 2017 , 7, 10380	4.9	9
88	Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 259-267	4.4	17

87	Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent. <i>Oncotarget</i> , 2017 , 8, 46549-46556	3.3	25
86	Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database. <i>Oncotarget</i> , 2017 , 8, 6206-6215	3.3	7
85	Risk factors of locoregional relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy following mastectomy and radiotherapy. <i>Oncotarget</i> , 2017 , 8, 39703-39710	3.3	5
84	The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer. <i>Oncotarget</i> , 2017 , 8, 44870-44880	3.3	14
83	Predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab. <i>Oncotarget</i> , 2017 , 8, 56626-56634	3.3	7
82	Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin. <i>Scientific Reports</i> , 2016 , 6, 30091	4.9	15
81	Clinicopathological Characteristics and Survival Outcomes in Invasive Papillary Carcinoma of the Breast: A SEER Population-Based Study. <i>Scientific Reports</i> , 2016 , 6, 24037	4.9	14
80	A Nomogram for Predicting the Pathological Response of Axillary Lymph Node Metastasis in Breast Cancer Patients. <i>Scientific Reports</i> , 2016 , 6, 32585	4.9	16
79	Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer. <i>Oncogene</i> , 2016 , 35, 1302-1313	9.2	102
78	Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 1653-62	12.9	53
77	Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value. <i>Cancer Research</i> , 2016 , 76, 2105-14	10.1	128
76	SSBP1 Suppresses TGF β -Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling. <i>Cancer Research</i> , 2016 , 76, 952-64	10.1	42
75	The 30 \pm TR signature defines a highly metastatic subgroup of triple-negative breast cancer. <i>Oncotarget</i> , 2016 , 7, 59834-59844	3.3	20
74	Genetic evaluation of BRCA1 associated a complex genes with triple-negative breast cancer susceptibility in Chinese women. <i>Oncotarget</i> , 2016 , 7, 9759-72	3.3	2
73	The BMP inhibitor DAND5 in serum predicts poor survival in breast cancer. <i>Oncotarget</i> , 2016 , 7, 14951-63	3.3	7
72	TAB3 O-GlcNAcylation promotes metastasis of triple negative breast cancer. <i>Oncotarget</i> , 2016 , 7, 22807-18	3.3	20
71	Pyrosequencing quantified methylation level of BRCA1 promoter as prognostic factor for survival in breast cancer patient. <i>Oncotarget</i> , 2016 , 7, 27499-510	3.3	14
70	Effect of nodal status on clinical outcomes of triple-negative breast cancer: a population-based study using the SEER 18 database. <i>Oncotarget</i> , 2016 , 7, 46636-46645	3.3	13

69	Elevated expression of RNA methyltransferase BCDIN3D predicts poor prognosis in breast cancer. <i>Oncotarget</i> , 2016 , 7, 53895-53902	3.3	13
68	Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status. <i>Oncotarget</i> , 2016 , 7, 41285-41293	3.3	32
67	High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer. <i>Oncotarget</i> , 2016 , 7, 64900-64909	3.3	37
66	Nomograms to estimate long-term overall survival and breast cancer-specific survival of patients with luminal breast cancer. <i>Oncotarget</i> , 2016 , 7, 20496-506	3.3	26
65	Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People's Republic of China. <i>OncoTargets and Therapy</i> , 2016 , 9, 2287-95	4.4	9
64	Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma: a population based study from SEER 18 database. <i>Oncotarget</i> , 2016 , 7, 22665-73	3.3	13
63	The membrane complement regulatory protein CD59 promotes tumor growth and predicts poor prognosis in breast cancer. <i>International Journal of Oncology</i> , 2016 , 48, 2015-24	4.4	20
62	The phosphorylation-specific association of STMN1 with GRP78 promotes breast cancer metastasis. <i>Cancer Letters</i> , 2016 , 377, 87-96	9.9	21
61	Suppression of Enhancer Overactivation by a RACK7-Histone Demethylase Complex. <i>Cell</i> , 2016 , 165, 331-42	56.2	98
60	Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. <i>Breast Cancer Research</i> , 2016 , 18, 33	8.3	106
59	Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 4859-4869	12.9	44
58	Polymorphisms in the kinesin-like factor 1 B gene and risk of epithelial ovarian cancer in Eastern Chinese women. <i>Tumor Biology</i> , 2015 , 36, 6919-27	2.9	3
57	Luminal B subtype: a key factor for the worse prognosis of young breast cancer patients in China. <i>BMC Cancer</i> , 2015 , 15, 201	4.8	26
56	CASP7 variants modify susceptibility to cervical cancer in Chinese women. <i>Scientific Reports</i> , 2015 , 5, 9225	4.9	10
55	Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer. <i>Cancer Research</i> , 2015 , 75, 1504-15	10.1	60
54	Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2015 , 16, 436-46	21.7	175
53	SENP1 inhibits the IH-induced apoptosis and nitric oxide production in BV2 microglial cells. <i>Biochemical and Biophysical Research Communications</i> , 2015 , 467, 651-6	3.4	4
52	Critical role of CDK11(p58) in human breast cancer growth and angiogenesis. <i>BMC Cancer</i> , 2015 , 15, 701	4.8	10

51	Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer. <i>BMC Medicine</i> , 2015 , 13, 254	11.4	12
50	The demographic features, clinicopathologic characteristics, treatment outcome and disease-specific prognostic factors of solitary fibrous tumor: a population-based analysis. <i>Oncotarget</i> , 2015 , 6, 41875-83	3.3	24
49	Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer. <i>International Journal of Nanomedicine</i> , 2015 , 10, 1969-75	7.3	10
48	Reduced Expression of TET1, TET2, TET3 and TDG mRNAs Are Associated with Poor Prognosis of Patients with Early Breast Cancer. <i>PLoS ONE</i> , 2015 , 10, e0133896	3.7	46
47	Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study. <i>Oncotarget</i> , 2015 , 6, 22985-95	3.3	12
46	Expression of autophagy-related proteins ATG5 and FIP200 predicts favorable disease-free survival in patients with breast cancer. <i>Biochemical and Biophysical Research Communications</i> , 2015 , 458, 816-22	3.4	25
45	A Prospective Evaluation of the Association between a Single Nucleotide Polymorphism rs3775291 in Toll-Like Receptor 3 and Breast Cancer Relapse. <i>PLoS ONE</i> , 2015 , 10, e0133184	3.7	12
44	High Levels of Nucleolar Spindle-Associated Protein and Reduced Levels of BRCA1 Expression Predict Poor Prognosis in Triple-Negative Breast Cancer. <i>PLoS ONE</i> , 2015 , 10, e0140572	3.7	42
43	Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study. <i>Oncotarget</i> , 2015 , 6, 9600-11	3.3	32
42	Difference between observed and expected number of involved lymph nodes reflects the metastatic potential of breast cancer independent to intrinsic subtype. <i>Oncotarget</i> , 2015 , 6, 16686-97	3.3	6
41	Differences in breast cancer characteristics and outcomes between Caucasian and Chinese women in the US. <i>Oncotarget</i> , 2015 , 6, 12774-82	3.3	15
40	Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy. <i>Oncotarget</i> , 2015 , 6, 18174-82	3.3	18
39	Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients. <i>Oncotarget</i> , 2015 , 6, 22227-38	3.3	31
38	Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial. <i>Oncotarget</i> , 2015 , 6, 18683-92	3.3	13
37	Host genotype and tumor phenotype of chemokine decoy receptors integrally affect breast cancer relapse. <i>Oncotarget</i> , 2015 , 6, 26519-27	3.3	16
36	Challenges to effective cancer control in China, India, and Russia. <i>Lancet Oncology, The</i> , 2014 , 15, 489-538	11.7	316
35	Enriched variations in TEK4 and breast cancer resistance to paclitaxel. <i>Nature Communications</i> , 2014 , 5, 3802	17.4	25
34	Inhibition of autophagy enhances the cytotoxic effect of PA-MSHA in breast cancer. <i>BMC Cancer</i> , 2014 , 14, 273	4.8	15

33	An aberrant spliced transcript of focal adhesion kinase is exclusively expressed in human breast cancer. <i>Journal of Translational Medicine</i> , 2014 , 12, 136	8.5	14
32	Marsupialization is the optimal treatment approach for keratocystic odontogenic tumour. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2014 , 42, 1540-4	3.6	29
31	Breast cancer in China. <i>Lancet Oncology, The</i> , 2014 , 15, e279-89	21.7	892
30	The effect of laterality and primary tumor site on cancer-specific mortality in breast cancer: a SEER population-based study. <i>PLoS ONE</i> , 2014 , 9, e94815	3.7	23
29	Prognostic value of myeloid differentiation primary response 88 and Toll-like receptor 4 in breast cancer patients. <i>PLoS ONE</i> , 2014 , 9, e111639	3.7	22
28	ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy. <i>PLoS ONE</i> , 2014 , 9, e114646	3.7	10
27	Impact of type 2 diabetes mellitus on the prognosis of early stage triple-negative breast cancer in People's Republic of China. <i>OncoTargets and Therapy</i> , 2014 , 7, 2147-54	4.4	12
26	PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2014 , 7, 543-52	4.4	11
25	ID2 predicts poor prognosis in breast cancer, especially in triple-negative breast cancer, and inhibits E-cadherin expression. <i>OncoTargets and Therapy</i> , 2014 , 7, 1083-94	4.4	12
24	Liver kinase B1 enhances chemoresistance to gemcitabine in breast cancer MDA-MB-231 cells. <i>Oncology Letters</i> , 2014 , 8, 2086-2092	2.6	9
23	Twist-1 up-regulation in carcinoma correlates to poor survival. <i>International Journal of Molecular Sciences</i> , 2014 , 15, 21621-30	6.3	52
22	Synovial sarcoma of the infratemporal fossa: A case report. <i>Oncology Letters</i> , 2014 , 8, 2165-2170	2.6	1
21	Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer. <i>Cancer Research</i> , 2014 , 74, 3399-407	10.1	31
20	Preoperative measurement of breast cancer overestimates tumor size compared to pathological measurement. <i>PLoS ONE</i> , 2014 , 9, e86676	3.7	10
19	Clinico-pathological features and prognosis of invasive micropapillary carcinoma compared to invasive ductal carcinoma: a population-based study from China. <i>PLoS ONE</i> , 2014 , 9, e101390	3.7	26
18	An elevated peripheral blood lymphocyte-to-monocyte ratio predicts favorable response and prognosis in locally advanced breast cancer following neoadjuvant chemotherapy. <i>PLoS ONE</i> , 2014 , 9, e111886	3.7	74
17	A polymorphism in JMJD2C alters the cleavage by caspase-3 and the prognosis of human breast cancer. <i>Oncotarget</i> , 2014 , 5, 4779-87	3.3	17
16	A recessive variant of XRCC4 predisposes to non- BRCA1/2 breast cancer in chinese women and impairs the DNA damage response via dysregulated nuclear localization. <i>Oncotarget</i> , 2014 , 5, 12218-32	3.3	4

15	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013 , 24, 2206-23	10.3	2048
14	Immediate postmastectomy breast reconstruction showed limited advantage in patient survival after stratifying by family income. <i>PLoS ONE</i> , 2013 , 8, e82807	3.7	6
13	Genetic variants in oxidative stress-related genes predict chemoresistance in primary breast cancer: a prospective observational study and validation. <i>Cancer Research</i> , 2012 , 72, 408-19	10.1	20
12	Bioinformatics study indicates possible microRNA-regulated pathways in the differentiation of breast cancer. <i>Science Bulletin</i> , 2010 , 55, 927-936		3
11	The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. <i>Breast Cancer Research and Treatment</i> , 2008 , 110, 99-109	4.4	84
10	Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival. <i>Journal of Biological Chemistry</i> , 2007 , 282, 4702-4710	5.4	387
9	The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006 , 132, 617-26	4.9	44
8	Breast conserving therapy in stage T1 & T2 breast cancer patients. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2005 , 17, 137-139	3.8	
7	The analysis of BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives. <i>Human Mutation</i> , 2003 , 22, 104	4.7	65
6	Tumor-specific DNA in plasma of breast cancer patients. <i>Anti-Cancer Drugs</i> , 2002 , 13, 353-7	2.4	10
5	Nipple aspiration in diagnosis of breast cancer. <i>Journal of Surgical Oncology</i> , 2001 , 20, 175-80		17
4	Fiberoptic ductoscopy for patients with nipple discharge. <i>Cancer</i> , 2000 , 89, 1512-1519	6.4	88
3	Fiberoptic ductoscopy for patients with nipple discharge 2000 , 89, 1512		5
2	Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis. <i>Breast Cancer Research and Treatment</i> , 1999 , 53, 263-9	4.4	26
1	p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. <i>International Journal of Cancer</i> , 1997 , 74, 529-34	7.5	90